Axitinib-d3

• CAT Number: R057544
• CAS Number: 1126623-89-9
• Molecular Formula: C₂₂H₁₅D₃N₄OS
• Molecular Weight: 389.49
• Purity: ≥95%
• Synonyms: N-(Methyl-d3)-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]benzamide; AG 013736-d3
• Storage: -20°C
• IUPAC Name: 2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]-N-(trideuteriomethyl)benzamide
• InChI: InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+/i1D3
• InChIKey: RITAVMQDGBJQJZ-VOTVRPQJSA-N
• SMILES: [2H]C([2H])([2H])NC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)/C=C/C4=CC=CC=N4

Axitinib-d3（Cat No.:R057544） is a deuterated variant of axitinib, a potent inhibitor used in cancer therapy, specifically for renal cell carcinoma. This compound, labeled with three deuterium atoms, enhances the precision of pharmacokinetic studies by providing increased stability and resistance to metabolic degradation. Axitinib-d3 is crucial for tracing the drug’s absorption, distribution, metabolism, and excretion, offering clearer insights into its therapeutic mechanisms and potential drug interactions. The deuteration allows for more accurate and sensitive analytical detection, crucial for optimizing dosage and improving the efficacy and safety of cancer treatments.